These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23395456)

  • 21. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Adamovich E
    Brachytherapy; 2015; 14(6):766-72. PubMed ID: 26489923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
    Lilleby W; Tafjord G; Raabe NK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    Tom MC; Nguyen JK; Lucianò R; Mian OY; Stephans KL; Ciezki JP; Smile TD; Wei W; McKenney JK; Magi-Galluzzi C; Tendulkar RD
    J Urol; 2019 Oct; 202(4):710-716. PubMed ID: 31059665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
    Pickles T; Morris WJ; Keyes M
    Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of race on biochemical disease recurrence after prostate brachytherapy.
    Yamoah K; Stone N; Stock R
    Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.
    Smolska-Ciszewska B; Miszczyk L; Białas B; Fijałkowski M; Plewicki G; Gawkowska-Suwińska M; Giglok M; Behrendt K; Nowicka E; Zajusz A; Suwiński R
    Radiat Oncol; 2015 Mar; 10():60. PubMed ID: 25884489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
    Stock RG; Berkowitz J; Blacksburg SR; Stone NN
    BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
    Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
    Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
    J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years.
    Yaxley JW; Lah K; Yaxley JP; Gardiner RA; Samaratunga H; MacKean J
    BJU Int; 2017 Jul; 120(1):56-60. PubMed ID: 27628127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of high-risk prostate cancer treated with brachytherapy combined with external-beam radiation therapy and androgen deprivation therapy.
    Chen J; Yan WG; Li HZ; Ji ZG; Zhou Y; Zhou ZE; Mai ZP
    Tumori; 2014; 100(5):524-8. PubMed ID: 25343547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.